The medication helps treat pulmonary arterial hypertension by diminishing symptoms linked to exercise. It is also used to reduce the rate of clinical deterioration among patients transitioning from epoprostenol.
The lot of the treprostinil injection 20 milligram per 20 milliliter solution was distributed to hospitals and wholesalers in summer 2022, according to the FDA.
A solution contaminated with a particulate matter can cause local irritation, swelling or blocked blood vessels in the heart, lungs or brain, which can lead to stroke or even death. No adverse events have been reported.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
